期刊
PHARMACEUTICS
卷 14, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics14102033
关键词
pancreatic ductal adenocarcinoma; nanomedicine; drug delivery; immunotherapy
资金
- Key research projects of Science & Technology of Sichuan Province [2022YFS0189]
- Fundamental Research Funds for the Central Universities [2022SCU12058]
Nanoparticle-based therapeutic strategies have shown promising applications in improving drug delivery and reversing the immunosuppressive tumor microenvironment for PDAC immunotherapy.
Immunotherapy has dramatically changed prognosis for patients with malignant tumors. However, as a non-immunogenic tumor, pancreatic ductal adenocarcinoma (PDAC) has a low response to immunotherapy. Factors that contribute to the inefficiency of PDAC immunotherapy include the tumor microenvironment (TME) and its dense stroma, which acts as a barrier for drug delivery and immune cell infiltration. Recent studies have shown that nanoparticle-based therapeutic strategies have more promising applications in improving drug delivery and reversing the immunosuppressive TME for PDAC. Therefore, nanomaterial-based therapeutic approaches are expected to enhance the effectiveness of immunotherapy and improve prognosis of patients with PDAC. Here, we outline the status and dilemma of PDAC immunotherapy, and summarize the latest advances in nanoparticle-based treatment strategies to enhance the efficacy of PDAC immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据